How Much Hope Is There For Alzheimer's Drugs?

Last night, Alzheimer's researchers held a celebration over their field's latest failure. A study of Eli Lilly's experimental Alzheimer's drug, solanezumab, failed to show a statistically significant benefit on its main goal, but every outcome seemed to go in the same direction. That yields some modicum of hope for other Alzheimer's drugs in development, particularly one from Biogen called aducanumab that is, in some ways, an amped up solanezumab. The results were webcast from the Clinical Trails in Alzheimer's Disease meeting in San Diego.